Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Nimbus Therapeutics, LLC et al v. Celgene Corporation et al
Case Number:
1:21-cv-06850
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
January 04, 2022
Nimbus, Bristol-Myers Drop Psoriasis Drug Dispute
Nimbus Therapeutics LLC agreed Tuesday to drop its case in New York federal court that sought to avoid selling Bristol-Myers Squibb Co. and its subsidiary Celgene Corp. a psoriasis drug the startup is developing.
-
October 15, 2021
Nimbus, Bristol-Myers Can't Sell Psoriasis Drug Amid Dispute
A New York federal court is blocking the sale of a psoriasis treatment under development by Nimbus Therapeutics LLC until after a dispute plays out with Bristol-Myers Squibb Co. over purchase rights for the drug candidate.
-
September 16, 2021
Bristol-Myers Says Nimbus Wants To Keep New Drug For Itself
Bristol-Myers Squibb Co. and its subsidiary Celgene Corp. hit back against a biotechnology company's bid to avoid selling them a psoriasis drug the startup is developing, complaining that Nimbus Therapeutics LLC's lawsuit seeking to escape its promise to shed the anti-inflammatory is a backdoor way of attacking the pharma giant's completed acquisition of Celgene.
-
August 16, 2021
Biotech Says Celgene-BMS Deal Threatens Drug Development
A biotechnology company fighting to avoid selling a psoriasis drug that's in development to Celgene, citing Bristol-Myers Squibb's $74 billion acquisition of the drugmaker and BMS' own competing treatment, invoked the Federal Trade Commission's outvoted Democrats in a New York federal court complaint on Friday.